Recent Updates
Recently added Catalysts

Durom Hip Resurfacing System

Phase 3

Advanced Hip Disease | Unknown | Other |Zimmer Biomet Holdings, Inc.|Last Updated: Apr 9, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment40
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00746616Durom(R) Hip Resurfacing System Multicenter TrialPHASE3 COMPLETED 40Jun 1, 2007Mar 1, 2011Apr 9, 2013 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
Durom Hip Resurfacing SystemDEVICEHip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
Unlock Study Design Details